CN105726745A - Medicine for treating lung cancers by combining traditional Chinese medicines and western medicines and preparation method thereof - Google Patents
Medicine for treating lung cancers by combining traditional Chinese medicines and western medicines and preparation method thereof Download PDFInfo
- Publication number
- CN105726745A CN105726745A CN201610170935.3A CN201610170935A CN105726745A CN 105726745 A CN105726745 A CN 105726745A CN 201610170935 A CN201610170935 A CN 201610170935A CN 105726745 A CN105726745 A CN 105726745A
- Authority
- CN
- China
- Prior art keywords
- parts
- medicine
- medicines
- traditional chinese
- herba
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/11—Pteridophyta or Filicophyta (ferns)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/39—Convolvulaceae (Morning-glory family), e.g. bindweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/40—Cornaceae (Dogwood family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/56—Loganiaceae (Logania family), e.g. trumpetflower or pinkroot
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a medicine for treating lung cancers by combining traditional Chinese medicines and western medicines and a preparation method thereof. The medicine is prepared from the following raw materials in parts by weight: 55-80 parts of pale butterflybush flower, 41-59 parts of stem of obtuseleaf erycibe, 31-49 parts of herb of Indian adenosma, 22-43 parts of fructus malvae, 20-34 parts of pith of himalayan stachyurus, 15-28 parts of stenoloma chusana, 10-18 parts of coral ardisia root, 6-15 parts of common St.John's wort herb, 3-14 parts of radix astragali preparata, 0.3-0.9 part of gemcitabine, 0.5-1.3 parts of mitomycin and 0.4-1.2 parts of pemetrexed. The medicine provided by the invention has the beneficial effects that the medicine combining traditional Chinese medicines and western medicines has better treatment effects on lung cancers than generally only used traditional Chinese medicines and western medicines; and the functions of traditional Chinese medicine components and western medicines can be furthest improved and the complementary and promoting effects can be exerted, thus improving the medicinal effects.
Description
Technical field
The present invention relates to the medicine of a kind of Lung Cancer with Integrated Traditonal Chinese Westren Medicine.
Background technology
Pulmonary carcinoma is that M & M increases the soonest, one of malignant tumor maximum to population health and life threat.Immediate and mid-term many countries all report that the M & M of pulmonary carcinoma the most substantially increases, and male lung cancer M & M all accounts for first of all malignant tumor.The cause of disease of pulmonary carcinoma is the clearest and the most definite, and great mass of data shows, long-term a large amount of smokings have very close relationship with pulmonary carcinoma.Existing research proves: the probability that long-term a large amount of smokers suffer from pulmonary carcinoma is 10～20 times of non-smoker, and the age starting smoking is the least, and the probability suffering from pulmonary carcinoma is the highest.Additionally, smoking not only directly affects my healthy, also the healthy of surrounding population is produced harmful effect, cause involuntary smoker's pulmonary carcinoma prevalence substantially to increase.The sickness rate of urbanite's pulmonary carcinoma is higher than rural area, and this may be relevant containing carcinogen with urban atmospheric pollution and flue dust.
The therapeutic modality of pulmonary carcinoma has excision or chemicotherapy etc. at present.Aforesaid way is relatively big to the physical impairment of patient, the most even can accelerate the death of patient.Simultaneously for Patients with Advanced Lung Cancer, above-mentioned therapeutic modality is unsuitable for.
Summary of the invention
The technical problem to be solved is: provide the pharmaceutical preparation of the Lung Cancer with Integrated Traditonal Chinese Westren Medicine that a kind of cure rate is high.
For solving above-mentioned technical problem, the technical solution used in the present invention is:
The medicine of the Lung Cancer with Integrated Traditonal Chinese Westren Medicine that the present invention provides, it is characterised in that be made up of the raw material of following weight portion: Flos Buddlejae 55-80 part, Caulis Erycibes 41-59 part, Herba Adenosmae 31-49 part, Fructus Malvae 22-43 part, Medulla Stachyuri (Medulla Helwingiae) 20-34 part, Stenoloma chusana 15-28 part, Radix Ardisiae Crenatae 10-18 part, Herba Hyperici Monogyni 6-15 part, Radix Astragali Preparata 3-14 part, gemcitabine 0.3-0.9 part, mitomycin 0.5-1.3 part, pemetrexed 0.4-1.2 part.
Preferably, the medicine that the present invention provides is made up of the raw material of Chinese medicine of following weight portion: Flos Buddlejae 63 parts, Caulis Erycibes 52 parts, Herba Adenosmae 40 parts, Fructus Malvae 32 parts, Medulla Stachyuri (Medulla Helwingiae) 26 parts, Stenoloma chusana 20 parts, Radix Ardisiae Crenatae 14 parts, Herba Hyperici Monogyni 8 parts, Radix Astragali Preparata 6 parts, gemcitabine 0.6 part, mitomycin 0.9 part, pemetrexed 0.9 part.
The present invention also provides for a kind of method preparing medicine, comprises the following steps:
(1) take Flos Buddlejae, Caulis Erycibes, Herba Adenosmae and Fructus Malvae and add distilled water immersion 5-9 hour, extract volatile oil with volatile oil extractor, be dried acquirement volatile oil with anhydrous magnesium sulfate, then use hydroxypropylβ-cyclodextrin inclusion, preparing clathrate, clathrate and medicinal residues are standby；
(2) take Medulla Stachyuri (Medulla Helwingiae), Stenoloma chusana, Radix Ardisiae Crenatae, add 75% ethanol extraction 3-6 time, each 1-3 hour, merge medicinal liquid, stand 24 hours, standby；
(3) after taking the medicinal residues mixing of Herba Hyperici Monogyni, Radix Astragali Preparata and step (1), then the ethanol adding the water of gross weight 5-6 times and the 70% of 0.3-1 times decocts 1.5-3h, double, merges the extracting solution of twice；
(4) taking step (2), the supernatant of (3), decompression recycling ethanol, be concentrated into 55 DEG C-65 DEG C, density is the extractum of 1.01-1.04, and concentrate drying makes powder；
(5) by the clathrate of step (1), the powder of (4) and gemcitabine, mitomycin, pemetrexed mix homogeneously.
Preferably, in step (1), the weight of distilled water is Flos Buddlejae, Caulis Erycibes, Herba Adenosmae and 3-6 times of Fructus Malvae gross weight, and temperature is 40-60 degree Celsius.
Preferably, the medicine of step (5) loads capsule, and the nt wt net weight of built-in medicine is 1 gram, and the using method of medicine is: oral, twice on the one, one time one.
Beneficial effects of the present invention:
The present invention provides the general simple traditional Chinese medical science of Drug therapy pulmonary carcinoma ratio of the combination of Chinese and Western medicine and western medical treatment better, can improve effect of Chinese medicine ingredients and Western medicine to greatest extent, play complementary and castering action, improve medicinal effects.
Chinese medicine and its effect of Western medicine component all act on lung, the heart, have detumescence, lung moistening, reduce phlegm, cough-relieving effect, cancerous cell is had the strongest inhibitory action.While anticancer, also promoting body constitution, invigorating the spleen and replenishing QI, nourishing blood to tranquillize the mind, to improve patient's resistance, reaches the effect for the treatment of both the principal and secondary aspects of a disease.
Chinese medicine used by the present invention, collocation rationally, can be alleviated the clinical symptoms of patients with lung cancer, alleviate the toxicity of Radiotherapy chemotherapy, improve treatment rate, extend life span.
Detailed description of the invention
Embodiment 1
The medicine of the Lung Cancer with Integrated Traditonal Chinese Westren Medicine that the present embodiment provides, is made up of the raw material of following weight: Flos Buddlejae 63 grams, Caulis Erycibes 52 grams, Herba Adenosmae 40 grams, Fructus Malvae 32 grams, Medulla Stachyuri (Medulla Helwingiae) 26 grams, Stenoloma chusana 20 grams, Radix Ardisiae Crenatae 14 grams, Herba Hyperici Monogyni 8 grams, Radix Astragali Preparata 6 grams, gemcitabine 0.6 gram, mitomycin 0.9 gram, pemetrexed 0.9 gram.
In preparation, the method for medicine, comprises the following steps:
(1) taking Flos Buddlejae, Caulis Erycibes, Herba Adenosmae and Fructus Malvae and add distilled water immersion 7 hours, extract volatile oil with volatile oil extractor, be dried acquirement volatile oil with anhydrous magnesium sulfate, then use hydroxypropylβ-cyclodextrin inclusion, prepare clathrate, clathrate and medicinal residues are standby；
(2) take Medulla Stachyuri (Medulla Helwingiae), Stenoloma chusana, Radix Ardisiae Crenatae, add 75% ethanol extraction 5 times, each 2 hours, merge medicinal liquid, stand 24 hours, standby；
(3) after taking the medicinal residues mixing of Herba Hyperici Monogyni, Radix Astragali Preparata and step (1), then the ethanol adding the water of gross weight 6 times and the 70% of 0.6 times decocts 2h, double, merges the extracting solution of twice；
(4) taking step (2), the supernatant of (3), decompression recycling ethanol, be concentrated into 60 DEG C, density is the extractum of 1.03, and concentrate drying makes powder；
(5) by the clathrate of step (1), the powder of (4) and gemcitabine, mitomycin, pemetrexed mix homogeneously.
In step (1), the weight of distilled water is 4 times of Flos Buddlejae, Caulis Erycibes, Herba Adenosmae and Fructus Malvae gross weight, and temperature is 50 degrees Celsius.
The medicine of step (5) is loaded capsule, and the nt wt net weight of built-in medicine is 1 gram, and the using method of medicine is: oral, twice on the one, one time one.
Embodiment 2
The medicine of the Lung Cancer with Integrated Traditonal Chinese Westren Medicine that the present embodiment provides, is made up of the raw material of following weight: Flos Buddlejae 80 grams, Caulis Erycibes 59 grams, Herba Adenosmae 49 grams, Fructus Malvae 43 grams, Medulla Stachyuri (Medulla Helwingiae) 34 grams, Stenoloma chusana 28 grams, Radix Ardisiae Crenatae 18 grams, Herba Hyperici Monogyni 15 grams, Radix Astragali Preparata 14 grams, gemcitabine 0.9 gram, mitomycin 1.3 grams, pemetrexed 1.2 grams.
In preparation, the method for medicine, comprises the following steps:
(1) taking Flos Buddlejae, Caulis Erycibes, Herba Adenosmae and Fructus Malvae and add distilled water immersion 9 hours, extract volatile oil with volatile oil extractor, be dried acquirement volatile oil with anhydrous magnesium sulfate, then use hydroxypropylβ-cyclodextrin inclusion, prepare clathrate, clathrate and medicinal residues are standby；
(2) take Medulla Stachyuri (Medulla Helwingiae), Stenoloma chusana, Radix Ardisiae Crenatae, add 75% ethanol extraction 6 times, each 3 hours, merge medicinal liquid, stand 24 hours, standby；
(3) after taking the medicinal residues mixing of Herba Hyperici Monogyni, Radix Astragali Preparata and step (1), then the ethanol adding the water of gross weight 6 times and the 70% of 1 times decocts 3h, double, merges the extracting solution of twice；
(4) taking step (2), the supernatant of (3), decompression recycling ethanol, be concentrated into 65 DEG C, density is the extractum of 1.04, and concentrate drying makes powder；
(5) by the clathrate of step (1), the powder of (4) and gemcitabine, mitomycin, pemetrexed mix homogeneously.
In step (1), the weight of distilled water is 6 times of Flos Buddlejae, Caulis Erycibes, Herba Adenosmae and Fructus Malvae gross weight, and temperature is 60 degrees Celsius.
The medicine of step (5) loads capsule, and the nt wt net weight of built-in medicine is 1 gram, and the using method of medicine is: oral, twice on the one, one time one.
Embodiment 3
The medicine of the Lung Cancer with Integrated Traditonal Chinese Westren Medicine that the present embodiment provides, is made up of the raw material of following weight: Flos Buddlejae 55 grams, Caulis Erycibes 41 grams, Herba Adenosmae 31 grams, Fructus Malvae 22 grams, Medulla Stachyuri (Medulla Helwingiae) 20 grams, Stenoloma chusana 15 grams, Radix Ardisiae Crenatae 10 grams, Herba Hyperici Monogyni 6 parts, Radix Astragali Preparata 3 parts, gemcitabine 0.3 part, mitomycin 0.5 part, pemetrexed 0.4 part.
In preparation, the method for medicine, comprises the following steps:
(1) taking Flos Buddlejae, Caulis Erycibes, Herba Adenosmae and Fructus Malvae and add distilled water immersion 5 hours, extract volatile oil with volatile oil extractor, be dried acquirement volatile oil with anhydrous magnesium sulfate, then use hydroxypropylβ-cyclodextrin inclusion, prepare clathrate, clathrate and medicinal residues are standby；
(2) take Medulla Stachyuri (Medulla Helwingiae), Stenoloma chusana, Radix Ardisiae Crenatae, add 75% ethanol extraction 3 times, each 1 hour, merge medicinal liquid, stand 24 hours, standby；
(3) after taking the medicinal residues mixing of Herba Hyperici Monogyni, Radix Astragali Preparata and step (1), then the ethanol adding the water of gross weight 5 times and the 70% of 0.3 times decocts 1.5h, double, merges the extracting solution of twice；
(4) taking step (2), the supernatant of (3), decompression recycling ethanol, be concentrated into 55 DEG C DEG C, density is the extractum of 1.01, and concentrate drying makes powder；
(5) by the clathrate of step (1), the powder of (4) and gemcitabine, mitomycin, pemetrexed mix homogeneously.
In step (1), the weight of distilled water is 3 times of Flos Buddlejae, Caulis Erycibes, Herba Adenosmae and Fructus Malvae gross weight, and temperature is 40-60 degree Celsius.
The medicine of step (5) loads capsule, and the nt wt net weight of built-in medicine is 1 gram, and the using method of medicine is: oral, twice on the one, one time one.
Clinical data:
1, physical data
Patients with Non-small-cell Lung 200 example is carried out clinical observation, and the age of patient is 33-76 year, 46 years old mean age.Wherein patients with terminal 113 example, early stage patient 87 example.
2, diagnostic criteria
Western medicine diagnose standard: Diagnosis of Non-Small Cell Lung standard uses specified standard in " the China's common cancer diagnosis and treatment specification " that Department of Medical Administration of Ministry of Health of the People's Republic of China writes.
3, Therapeutic Method
Use medicine of the present invention, oral, twice on the one, one time one.
4, efficacy assessment standard:
Complete incidence graph (CR): all visible focuses are wholly absent, and at least maintain more than 4 weeks；
Part alleviates (PR): the product in longest diameter of tumor and maximum perpendicular footpath reduces more than 50%, is in progress without other focuses, occurs without any new focus；
Stable disease unchanged (SD): the product in longest diameter of tumor and maximum perpendicular footpath reduces less than 50%, or increase less than 25%, occur without any new focus；
Progress (PD): the product in longest diameter of tumor and maximum perpendicular footpath increases more than 25%；CR+PR is total effective rate.
5, therapeutic effect: complete incidence graph: 166 examples, part alleviation: 28 examples, stable disease is unchanged: 6 examples, PD:0 example.Total effective rate is 100%.
Model case
Case 1: Lee, man, 49 years old.Patient is diagnosed as pulmonary carcinoma through CT examination, uses the medicine of the present invention to treat, and after 2 courses for the treatment of, patients symptomatic substantially alleviates.Continuing to take 3 courses for the treatment of, patient's focal symptom is wholly absent, and follows up a case by regular visits to 2 years so far without recurrence.
Case 2: slowly certain, female, 36 years old.Chronic cough, hemoptysis, become thin, be pulmonary carcinoma through hospital diagnosis, after taking 3 courses for the treatment of of medicine of the present invention, cough hemoptysis stops, and feed is normal, continues to take 2 courses for the treatment of, transference cure.
Case 3: Lu, man, 52 years old.Patient is because feeling of oppression and pain in the chest is to hospital's CT examination: CT examination finds that there is 3.9 × 4.6cm shade in pulmonary, is diagnosed as pulmonary carcinoma.Through taking medicine of the present invention, after 3 courses for the treatment of, CT examination pulmonary shadow is reduced into 2.0 × 2.3cm, continues to take 6 courses for the treatment of, and CT examination pulmonary shadow disappears, and follows up a case by regular visits to survive so far.
Case 4: beam, man, 53 years old.Patient has the smoking history of more than ten years.Cough, sputum mixed with blood, the symptom such as chest pain occur in this year, checks and be diagnosed as pulmonary carcinoma.Through taking medicine of the present invention, after 3 courses for the treatment of, patients symptomatic substantially alleviates, and continues to take 3 courses for the treatment of, and patients symptomatic is wholly absent, and follows up a case by regular visits to without recurrence.
Case 5: Zhao, female, 62 years old.Patient, because feeling of oppression and pain in the chest is to hospital's CT examination, is diagnosed as alveolar cell carcinoma.Through taking medicine of the present invention, after 4 courses for the treatment of, pulmonary shadow reduces, and continues to take 3 courses for the treatment of, and pulmonary shadow is wholly absent, and follows up a case by regular visits to survive so far.
Claims (4)
1. the medicine of Lung Cancer with Integrated Traditonal Chinese Westren Medicine, it is characterised in that be made up of the raw material of following weight portion: Flos Buddlejae 55-80 part, Caulis Erycibes 41-59 part, Herba Adenosmae 31-49 part, Fructus Malvae 22-43 part, Medulla Stachyuri (Medulla Helwingiae) 20-34 part, Stenoloma chusana 15-28 part, Radix Ardisiae Crenatae 10-18 part, Herba Hyperici Monogyni 6-15 part, Radix Astragali Preparata 3-14 part, gemcitabine 0.3-0.9 part, mitomycin 0.5-1.3 part, pemetrexed 0.4-1.2 part.
Medicine the most according to claim 1, it is characterised in that be made up of the raw material of Chinese medicine of following weight portion: Flos Buddlejae 63 parts, Caulis Erycibes 52 parts, Herba Adenosmae 40 parts, Fructus Malvae 32 parts, Medulla Stachyuri (Medulla Helwingiae) 26 parts, Stenoloma chusana 20 parts, Radix Ardisiae Crenatae 14 parts, Herba Hyperici Monogyni 8 parts, Radix Astragali Preparata 6 parts, gemcitabine 0.6 part, mitomycin 0.9 part, pemetrexed 0.9 part.
3. the method preparing medicine described in any of the above-described claim, it is characterised in that comprise the following steps:
(1) take Flos Buddlejae, Caulis Erycibes, Herba Adenosmae and Fructus Malvae and add distilled water immersion 5-9 hour, extract volatile oil with volatile oil extractor, be dried acquirement volatile oil with anhydrous magnesium sulfate, then use hydroxypropylβ-cyclodextrin inclusion, preparing clathrate, clathrate and medicinal residues are standby；
(2) take Medulla Stachyuri (Medulla Helwingiae), Stenoloma chusana, Radix Ardisiae Crenatae, add 75% ethanol extraction 3-6 time, each 1-3 hour, merge medicinal liquid, stand 24 hours, standby；
(3) after taking the medicinal residues mixing of Herba Hyperici Monogyni, Radix Astragali Preparata and step (1), then the ethanol adding the water of gross weight 5-6 times and the 70% of 0.3-1 times decocts 1.5-3h, double, merges the extracting solution of twice；
(4) taking step (2), the supernatant of (3), decompression recycling ethanol, be concentrated into 55 DEG C-65 DEG C, density is the extractum of 1.01-1.04, and concentrate drying makes powder；
(5) by the clathrate of step (1), the powder of (4) and gemcitabine, mitomycin, pemetrexed mix homogeneously.
Method the most according to claim 3, it is characterised in that in step (1), the weight of distilled water is Flos Buddlejae, Caulis Erycibes, Herba Adenosmae and 3-6 times of Fructus Malvae gross weight, and temperature is 40-60 degree Celsius.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610170935.3A CN105726745A (en) | 2016-03-24 | 2016-03-24 | Medicine for treating lung cancers by combining traditional Chinese medicines and western medicines and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610170935.3A CN105726745A (en) | 2016-03-24 | 2016-03-24 | Medicine for treating lung cancers by combining traditional Chinese medicines and western medicines and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105726745A true CN105726745A (en) | 2016-07-06 |
Family
ID=56251916
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610170935.3A Pending CN105726745A (en) | 2016-03-24 | 2016-03-24 | Medicine for treating lung cancers by combining traditional Chinese medicines and western medicines and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105726745A (en) |
-
2016
- 2016-03-24 CN CN201610170935.3A patent/CN105726745A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102228599B (en) | Chinese medicinal preparation for treating tumor | |
| CN102258563A (en) | Anti-cancer medicinal composition and Chinese medicinal composition | |
| CN102861284B (en) | Traditional Chinese medicine compound preparation for treating non-small cell lung cancer and preparation method thereof | |
| CN101780136A (en) | Medicine and food dual-purpose traditional Chinese medicine composition with anti-tumor activity and immunoregulation effect and application thereof | |
| CN105169212A (en) | Traditional Chinese medicine composition for treating chronic gastritis | |
| CN102861193B (en) | Traditional Chinese medicine composition for treating gastric cancer | |
| CN104826029A (en) | Traditional Chinese medicine composition for treating breast cancer and application of traditional Chinese medicine composition | |
| CN102048939B (en) | Medicament for treating sinus bradycardia | |
| CN102028924A (en) | Medicinal composition for late gastric cancer | |
| CN1730093A (en) | Chinese traditional medicine preparation for treating cancer and application thereof | |
| CN105726745A (en) | Medicine for treating lung cancers by combining traditional Chinese medicines and western medicines and preparation method thereof | |
| CN103623246B (en) | A kind of Chinese medicine preparation for the treatment of hypertension and complication thereof | |
| CN105687450A (en) | Medicament capable of treating lung cancer by virtue of combined treatment of traditional Chinese medicine and western medicine | |
| CN101020002B (en) | Compound Chinese medicine preparation for assisting tumor radiotherapy and its preparation method | |
| CN105641171A (en) | Medicine for treating lung cancer by combination of Chinese traditional medicine and western medicine and preparation method thereof | |
| CN103736051A (en) | Hemangioma nursing medicament and preparation method thereof | |
| CN104524359B (en) | A kind of Chinese medicine composition, its preparation method and application | |
| CN102000303B (en) | Compound traditional Chinese medicine preparation for suppressing tumors | |
| CN108143818A (en) | A kind of Chinese medicine composition for controlling cough and asthma | |
| CN106692821A (en) | Traditional Chinese medicine preparation for treating neurosurgical postoperative headache | |
| CN105943579A (en) | Pharmaceutical composition for treating gastric cancer and preparation method of pharmaceutical composition | |
| CN1055020C (en) | Method for preparing anti-tumour Chinese medicinal liquor | |
| CN104606377A (en) | Traditional Chinese medicinal composition for treating gastritis | |
| CN103816468B (en) | A kind of capsule treating gastric cancer and preparation method thereof | |
| CN110302247A (en) | A kind of pharmaceutical composition assisting in the treatment of prostate cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160706 |